359P Overall survival of palbociclib (PAL) + endocrine therapy (ET) in Japanese patients with hormone receptor-positive (HR+)/ human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) in the 1st line (1L) or 2nd line (2L) setting: A multicenter observational study - Nakayama, T.; Nagai, S.E.; Hattori, M.; Yoshinami, T.; Masuda, H.; Okamura, T.; Watanabe, K-I.; Tsuneizumi, M.; Takabatake, D.; Harao, M.; Yasojima, H.; Oshiro, C.; et al. (Annals of Oncology, 2024)